EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients

Jiun-I Lai iD, Ting-Hao Kuo, Kuan-Jung Huang, Laura Min Xuan Chai, Mei-Hsuan Lee, Chun-Yu Liu iD, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Cheng-Chih Hsu, Ta-Chung Chao

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Jiun-I Lai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Department of Medicine, National Yang-Ming Ming Chiao Tung University, Taipei, Taiwan, Republic of China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neutropenia, Piperazines, Pyridines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council, Taiwan Clinical Oncology Research Foundation, Melissa Lee Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CDK4/6 inhibitors (CDK4/6i) have shown great efficacy in prolonging progression-free survival and is the current standard of care for hormone positive (HR(+)) metastatic breast cancer (mBC). Despite well tolerability and ease of use, the most common side effect of CDK4/6i is myelosuppression, with neutropenia the most prevalent adverse effect. Studies show that the prevalence and severity of neutropenia are more marked in Asian patients, although details remain obscure.

Methods

In this study, we retrospectively analyzed 105 Taiwanese patients who received palbociclib for HR(+) HER2(−) mBC at the Taipei Veterans General Hospital. To investigate a possible genetic association for high prevalence of neutropenia, we queried the Taiwan Biobank with publicly available germline databases (ALFA, gnomAD, ExAC, 1000 Genomes project, HapMap), for the allele frequencies of 4 neutropenia-related SNPs (ABCB1_rs1045642, ABCB1_rs1128503, ERCC1_rs3212986, ERCC1_rs11615) and compared between different ethnicities. In addition, one of the patients was a long-term patient with peritoneal dialysis. We quantified the levels of palbociclib in her serum and peritoneal fluid by liquid chromatography-mass spectrometry (LC-MS).

Results

Interestingly, in our cohort, early neutropenia nadir (occurred within 56 days of start) was associated with worse treatment outcome, while occurrence of grade 3/4 neutropenia was associated with better outcome. We observed an extremely high incidence of neutropenia (96.2% any grade, 70.4% grade 3/4). In the analyzed germline databases, we discovered a higher SNP frequency of the T allele in ABCB1_rs1128503, a lower frequency of T allele in ABCB1_rs1045642, and a higher SNP frequency of G allele in ERCC1_rs11615. We observed that palbociclib levels in peritoneal dialysate ranged from around 20-50 ppb, and serum levels reached 100-110 ppb during drug administration and decreased to <10 ppb during discontinuation.

Conclusion

Our retrospective analysis of real world palbociclib use reveals an association with grade 3/4 neutropenia with better outcome and early neutropenia nadir with worse outcome. Our findings of Asian specific SNPs support a predisposition toward profound and prevalent neutropenia in Asian patients under CDK4/6i. We also report the first pharmacokinetics analysis on a patient with peritoneal dialysis receiving CDK4/6i. In summary, our study provides novel clinical and genotypic insights into CDK4/6i associated neutropenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeutropeniaPiperazinesPyridinesFemaleHumansRetrospective StudiesPrevalenceErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsCyclin-Dependent Kinase 4

Stichwörter der Autor:innen

CDK4/6neutropeniapalbociclibperitoneal dialysis

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4PiperazinesPyridinespalbociclib

Autor:innen und Institutionen

  • Institute of Clinical Medicine, Department of Medicine, National Yang-Ming Ming Chiao Tung University, Taipei, Taiwan, Republic of China.
  • Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
  • Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
  • Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
  • Department of Chemistry, National Taiwan University, Taipei, Taiwan, Republic of China.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.

ORCID-Profile: Jiun-I Lai, Chun-Yu Liu

Förderung

  • National Science and Technology Council
  • Taiwan Clinical Oncology Research Foundation
  • Melissa Lee Cancer Foundation
  • Taipei Veterans General Hospital

Zitieren

APA

Lai, J. I., Kuo, T. H., Huang, K. J., Chai, L. M. X., Lee, M. H., Liu, C. Y., Tsai, Y. F., Huang, C. C., Tseng, L. M., Hsu, C. C., & Chao, T. C. (2024). Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The Oncologist. https://doi.org/10.1093/oncolo/oyad304

Vancouver

Lai JI, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, et al. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The Oncologist. 2024. doi:10.1093/oncolo/oyad304

BibTeX
@article{Lai2024,
  author = {Lai, Jiun-I and Kuo, Ting-Hao and Huang, Kuan-Jung and Chai, Laura Min Xuan and Lee, Mei-Hsuan and Liu, Chun-Yu and Tsai, Yi-Fang and Huang, Chi-Cheng and Tseng, Ling-Ming and Hsu, Cheng-Chih and Chao, Ta-Chung},
  title = {Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad304}
}
Kostenlos starten →